Cargando…

Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study

Apatinib (Jiangsu HengRui Medicine Co. Ltd), a vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase inhibitor, has been proven to be safe and to significantly prolong survival in advanced chemotherapy-refractory gastric cancer. This study aimed to assess and compare the efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Yesong, Tang, Jinhai, Huang, Xin-En, Cao, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380695/ https://www.ncbi.nlm.nih.gov/pubmed/30732125 http://dx.doi.org/10.1097/MD.0000000000013908

Ejemplares similares

Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma
por: Gao, Shen, et al.
Publicado: (2022)

Efficacy and Safety of Apatinib in the Treatment of Chemotherapy-Refractory Metastatic Colorectal Cancer: A Systematic Review
por: Khan, Aujala Irfan, et al.
Publicado: (2022)

Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study
por: Wang, Fen, et al.
Publicado: (2020)

Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study
por: Wang, Chunjing, et al.
Publicado: (2023)

Effective treatment of apatinib for chemotherapy-refractory advanced gastric carcinoma with AFP-secretion and HER2-positivity: A case report
por: Ding, Xinjing, et al.
Publicado: (2021)

Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment
por: Bai, Ming, et al.
Publicado: (2021)

Multicenter phase II study of apatinib treatment for metastatic gastric cancer after failure of second-line chemotherapy
por: Ruan, Hanguang, et al.
Publicado: (2017)

Safety and efficacy of apatinib combined with iodine-125 in chemotherapy-refractory advanced lung cancer: A case report
por: Zhang, Yunchao, et al.
Publicado: (2020)

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
por: Zhang, Le, et al.
Publicado: (2023)

Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma
por: Lu, Bin, et al.
Publicado: (2019)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
por: Wang, Jiaqiang, et al.
Publicado: (2023)

Safety Analysis of Apatinib Combined with Chemotherapy in the Treatment of Advanced Gastric Carcinoma: A Randomised Controlled Trial
por: Yuan, Min, et al.
Publicado: (2021)

Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma
por: Zhou, Na, et al.
Publicado: (2016)

Neoadjuvant apatinib plus tegafur/gimeracil/oteracil potassium (S‑1)/oxaliplatin chemotherapy vs. chemotherapy alone in patients with locally advanced gastric carcinoma
por: Wang, Zhenfeng, et al.
Publicado: (2022)

Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study
por: Li, Jin, et al.
Publicado: (2023)

Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review
por: Liu, Ying-ying, et al.
Publicado: (2019)

Effectiveness and Safety of Apatinib in Patients with Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction: A Prospective Observation Study
por: Shen, Bo, et al.
Publicado: (2020)

Efficacy and safety of apatinib combined with chemotherapy for the treatment of advanced gastric cancer in the Chinese population: a systematic review and meta-analysis
por: Cheng, Honggang, et al.
Publicado: (2018)

Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial
por: Lin, Jian-Xian, et al.
Publicado: (2021)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
por: Gong, Taojun, et al.
Publicado: (2022)

Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study
por: Lin, Haimin, et al.
Publicado: (2019)

Efficacy and safety of apatinib in patients with untreated or chemotherapy-refractory soft tissue sarcoma: a multicenter, phase 2 trial
por: Yu, Wenxi, et al.
Publicado: (2022)

Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC
por: Zhou, Peng-zhe, et al.
Publicado: (2021)

Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort
por: Manfredi, Sylvain, et al.
Publicado: (2022)

Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study
por: Zhu, Anjie, et al.
Publicado: (2019)

Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report
por: Deng, Linghui, et al.
Publicado: (2017)

Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study
por: Tang, Jing, et al.
Publicado: (2019)

Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study
por: Zhao, Shen, et al.
Publicado: (2020)

Efficacy and Safety of Apatinib for Elderly Patients with Advanced or Metastatic Gastric Cancer After Failure of at Least First-Line Chemotherapy: A Multi-Center, Single-Arm, Phase II Study
por: Ren, Dengfeng, et al.
Publicado: (2021)

Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study
por: Zhang, Ge, et al.
Publicado: (2021)

Histologic Lymph Nodes Regression after Preoperative Chemotherapy as Prognostic Factor in Non-metastatic Advanced Gastric Adenocarcinoma
por: Bausys, Augustinas, et al.
Publicado: (2021)

Is Treatment-Emergent Toxicity a Biomarker of Efficacy of Apatinib in Gastric Cancer?
por: Lee, Hyo Jin, et al.
Publicado: (2016)

Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study
por: Zhang, Yan, et al.
Publicado: (2022)

Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma
por: Lin, Daniel, et al.
Publicado: (2023)

Neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: our experience in the elderly
por: Bugiantella, W, et al.
Publicado: (2009)

A Phase II Study of Apatinib in Patients with Chemotherapy‐Refractory Esophageal Squamous Cell Carcinoma (ESO‐Shanghai 11)
por: Chu, Li, et al.
Publicado: (2021)

Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer
por: Kim, S T, et al.
Publicado: (2005)

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
por: Zeng, Da-xiong, et al.
Publicado: (2017)

A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
por: Weinberg, Benjamin A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g4r0tiit7qplad6cm51g7hl3ru